OTTAWA, Ontario, June 13, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has signed a distribution agreement for OxC-beta™ Livestock in Thailand with FAITH (Feed and Ingredients Technology Hub), a member of the BIS Group of Companies.
The agreement, which is not exclusive, includes Thailand, Myanmar, Cambodia, Laos, Malaysia, Vietnam and Indonesia, and allows FAITH to immediately distribute in Thailand as well as Myanmar and Cambodia, as both these countries follow Thailand’s regulatory authority, and where Avivagen has already obtained regulatory approval. The introduction to FAITH was arranged by Ms. Jaruwan Sanping, Avivagen’s Thailand-based consultant, and is evidence of the tremendous sales potential of the Asia-Pacific region, with a growing middle class and annual feed consumption of 381mm tones, representing 35.6% of the world’s total.
In conjunction with this agreement, FAITH announced that it has completed a successful trial with OxC-beta™ Livestock on a commercial pig farm in Thailand with one of its customers, and that the trial results met all of its expectations. Thailand is known for its leadership throughout the region for reducing the use of antibiotics in animal feed. The agreement with FAITH demonstrates Avivagen’s ability to provide a much-needed alternative to help alleviate the global problem of antibiotic resistance.
About Avivagen Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .
About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology arises from Avivagen’s discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors. Specifically, Avivagen has discovered the naturally occurring compound that is the actual source of β-carotene’s non-vitamin A activity and uses the synthetic version of the compound as the source of activity of Avivagen’s OxC-beta™ products. Importantly, the OxC-beta™ compound is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.
About Vivamune™ Health Chews (Vivamune) Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com .
Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the process and timing for seeking regulatory approvals, the possibility of receiving such approvals, the activities of FAITH and the possible outcomes of those activities and the possibility for registration in Laos, Malaysia, Vietnam and Indonesia to increase Avivagen Inc.’s sales are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen may not gain market acceptance or regulatory approval in Laos, Malaysia, Vietnam or Indonesia, in the time frame anticipated or at all and, if regulatory approval is granted, it may not have the anticipated effects on Avivagen Inc.’s sales due to many factors, many of which are outside of Avivagen’s control. The distribution agreement described above is not a guarantee of sales of any specified amount of Avivagen’s products. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information: Avivagen Inc. Drew Basek Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail: d.basek@avivagen.com
Kym Anthony Chairman & Interim CEO 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website: www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
